13 May 2020

The Academy of Medical Sciences has elected 50 of the UK’s most prominent biomedical and health scientists to their Fellowship, it has been announced today. Amongst the scientists was tranScrip’s Managing Partner, Dr Flic Gabbay.

The prestigious award recognises the outstanding contributions Dr Gabbay has made to medical science and medicines. This has been awarded to her based on her significant initiatives in pharmaceutical medicine both for contributing to the introduction of many innovative medicines and setting standards in medicines research, development, and oversight.

Flic has worked in the industry for more than 30 years and has held a number of Board level, CEO and therapeutic area head positions in big pharma, biotech and CROs in both Europe and North America. She has extensive experience of working on the development, submission and launches of products in infection, respiratory disease, arthritis, immunology, chronic kidney disease and oncology. Her contributions go well beyond the Faculty, working on numerous global drug development guidelines for rheumatology, epilepsy, ethics, antibiotics, antivirals, respiratory medicine, and the pharmaceutical panel for the NHS-HTA, the forerunner of UK HTA. Flic is a committed entrepreneur and was founding Chairman of the Royal College of Physicians of London steering group that set-up the UK Faculty of Pharmaceutical Medicine (FPM), was its first Academic Registrar and is currently Vice President. Flic started Gabbay Group, a CRO acquired by PPD, was Founding Chairman of Phico Therapeutics and has also been CEO of two small biotech companies. In 2008, Flic co-founded tranScrip, a global leading specialist pharma consultancy.

Flic commented, “I am delighted to be awarded the Fellowship, which not only honors myself but the colleagues I have worked with over the years in pharmaceutical research and development, the Faculty of Pharmaceutical Medicine and not least in tranScrip. We have all been passionate about not only medical innovation, but also ensuring that standards are adhered to make innovation ethical, efficient, and meet patient’s needs as rapidly as possible. I am looking forward to working with my esteemed new colleagues in the Academy of Medical Sciences and contributing to the scientific excellence they support.”